Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Blood (2022) 140 (Supplement 1): 9259–9260.

https://doi.org/10.1182/blood-2022-169623

Published: 2022

Journal Articles

Shared and Distinct Genetic Features in Human and Canine B-Cell Lymphomas

Tiana Hillman, Matthew Cheung, Bruno M. Grande, Kevin R Bushell, Sarah E. Arthur, Miguel Alcaide, Nicole Thomas, Kostiantyn Dreval, Jovanveer Shoker, Krishanna Campbell, Stephanie Wong, Ryan D Morin, Krysta M. Coyle

Blood (2021) 138 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2021-153928

Published: 2021

Journal Articles

Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Nicole Thomas, BSc, Christopher Rushton, BSc, Jeffrey Tang, Miguel Alcaide, PhD, Shannon Healy, PhD, Adele Telenius, Anja Mottok, MD PhD, David W. Scott, MBChB, PhD, Christian Steidl, MD, Ryan D Morin, PhDBSc,MSc

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-137700

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

NFKBIZ 3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Nicole Thomas, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Shannon Healy, PhD, Anja Mottok, MD PhD, David W. Scott, MBChB, PhD, Christian Steidl, MD, Ryan D. Morin, PhD

Blood (2019) 134 (Supplement_1): 296.

https://doi.org/10.1182/blood-2019-127421

Published: 2019

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH

Laura K. Hilton, Jeffrey Tang, Susana Ben-Neriah, Miguel Alcaide, Aixiang Jiang, Bruno M. Grande, Christopher K. Rushton, Merrill Boyle, Barbara Meissner, David W. Scott, Ryan D. Morin

Blood (2019) 134 (18): 1528–1532.

https://doi.org/10.1182/blood.2019002600

Published: 2019

Includes: Supplemental data

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD

Blood (2018) 132 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2018-99-117333

Published: 2018

Journal Articles

Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma

Sarah E Arthur, BSc, Anja Mottok, MD PhD, Miguel Alcaide, PhD, Christopher Rushton, BSc, Bruno M. Grande, BSc, Daisuke Ennishi, MDPhD, Jordan Davidson, BSc, Kevin R Bushell, BSc, MSc, Randy D. Gascoyne, MD, Marco A Marra, PhD, Joseph M Connors, MD, Gregg B Morin, PhD, David W. Scott, MD PhD FRACP, FRCPA, Christian Steidl, MD, Ryan D. Morin, PhDBSc,MSc

Blood (2017) 130 (Supplement 1): 1228.

https://doi.org/10.1182/blood.V130.Suppl_1.1228.1228

Published: 2017

Journal Articles

Identification of Recurrent Non-Coding Driver Mutations in Non-Hodgkin Lymphomas through Integrative Genomic Analysis of 777 Patients

Blood (2017) 130 (Supplement 1): 36.

https://doi.org/10.1182/blood.V130.Suppl_1.36.36

Published: 2017

Journal Articles

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Blood (2016) 128 (2): 185–194.

https://doi.org/10.1182/blood-2016-02-699520

Published: 2016

Includes: Supplemental data

Journal Articles

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Sarit Assouline, Michael Crump, MD, Torsten Holm Nielsen, Miguel Alcaide, B. Sc., Ph. D., David Macdonald, MD FRCPC, Axel Tosikyan, Tina Haliotis, Celia Greenwood, Kathleen Klein Oros, Ryan Morin, PhD, Nathalie Johnson, MD PhD, Koren Kathleen Mann, PhD

Blood (2015) 126 (23): 2719.

https://doi.org/10.1182/blood.V126.23.2719.2719

Published: 2015

Journal Articles

Genetic inactivation of TRAF3 in canine and human B-cell lymphoma

Kevin R. Bushell, Yukyoung Kim, Fong Chun Chan, Susana Ben-Neriah, Andrew Jenks, Miguel Alcaide, Daniel Fornika, Bruno M. Grande, Sarah Arthur, Randy D. Gascoyne, Christian Steidl, Ryan D. Morin

Blood (2015) 125 (6): 999–1005.

https://doi.org/10.1182/blood-2014-10-602714

Published: 2015

Includes: Supplemental data

NARROW

Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Shared and Distinct Genetic Features in Human and Canine B-Cell Lymphomas

Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

NFKBIZ 3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Functional Investigation of the Gene NFKBIZ and the Impact of 3'UTR Mutations in Diffuse Large B-Cell Lymphoma

Identification of Recurrent Non-Coding Driver Mutations in Non-Hodgkin Lymphomas through Integrative Genomic Analysis of 777 Patients

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Genetic inactivation of TRAF3 in canine and human B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only